Table 2.

Univariate outcomes of patients who underwent allogeneic transplants for AML, ALL, CML, MDS and had Invasive fungal infection within 12 months prior to transplant vs. those who had no documented invasive fungal infection within 12 months prior to transplant, reported to the CIBMTR, from 2001 to 2009

Outcomes	Pre-tx invasive fungal infection		All others		P-value
	N Eval	Probability (95% CI)	N Eval	Probability (95% CI)
Overall survival from transplant	825		10247
@ 1 year		54 (48–55)%		65(64–66) %	<.0001
@ 3 years		35 (31–38)%		50 (49–51)%	<.0001
@ 5 years		30 (26–34)%		45 (44–46)%	<.0001
Relapse	813		10146
@ 1 year		33 (29–36) %		26(25–27) %	0.0002
@ 3 years		42 (39–46) %		35 (34–36)%	<.0001
@ 5 years		45 (41–49) %		39 (38–40)%	0.0018
Non-relapse mortality	813		10146
@ 1 year		23 (20–26) %		17(17–18) %	0.0003
@ 3 years		27 (24–30) %		22 (21–23)%	0.0046
@ 5 years		29 (26–32) %		25 (24–26)%	0.0347
Disease free survival	813		10146
@ 1 year		45 (41–48) %		57(56–58) %	<.0001
@ 3 years		31(28–34) %		44 (43–45)%	<.0001
@ 5 years		27(23–31) %		37 (36–38)%	<.0001
Acute GVHD (grade 2–4)	822		10224
@ 100 days		34 (31–37) %		39(38–40) %	0.0022
Chronic GVHD	810		10098
@ 1 year		31 (28–34) %		39(38–40) %	<.0001
@ 3 years		35 (32–38) %		44 (43–45)%	<.0001
@ 5 years		36 (32–39) %		45 (44–46)%	<.0001
Fungal infection within 1 year post TX	824		10168
@ 100 days		17 (15–20) %		11(10–11) %	<.0001
@ 6 months		21 (19–24) %		14 (13–14)%	<.0001
@ 1 years		24(21–27) %		17 (16–18)%	<.0001